相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
Deepak Raj et al.
GUT (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
Jason J. Lohmueller et al.
ONCOIMMUNOLOGY (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Christopher C. Kloss et al.
MOLECULAR THERAPY (2018)
A Rapamycin-Activated Caspase 9-Based Suicide Gene
Maria Stavrou et al.
MOLECULAR THERAPY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer
Wenqi Chu et al.
BIOSCIENCE TRENDS (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta et al.
NATURE (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Katherine C. Pehlivan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Sophie Viaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Erhao Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Masked Chimeric Antigen Receptor for Tumor-Specific Activation
Xiaolu Han et al.
MOLECULAR THERAPY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
Dominik Bachmann et al.
Oncotarget (2017)
Retargeting of T lymphocytes to PSCA-or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology UniCAR
Anja Feldmann et al.
ONCOTARGET (2017)
Antigen Loss variants: catching Hold of escaping Foes
Maulik Vyas et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
Hamid R. Mirzaei et al.
FRONTIERS IN IMMUNOLOGY (2017)
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Katerina T. Xenaki et al.
FRONTIERS IN IMMUNOLOGY (2017)
A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
Susann Albert et al.
ONCOIMMUNOLOGY (2017)
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
Kristen M. Hege et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Dina Schneider et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Mechanisms regulating T-cell infiltration and activity in solid tumors
E. Lanitis et al.
ANNALS OF ONCOLOGY (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors
Christine Ambrose et al.
CANCER RESEARCH (2017)
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer
Yu Cao et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells
Maria Michela D'Aloia et al.
CYTOTHERAPY (2016)
Biology and clinical application of CAR T cells for B cell malignancies
Marco L. Davila et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Versatile strategy for controlling the specificity and activity of engineered T cells
Jennifer S. Y. Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
David T. Rodgers et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Christoph T. Ellebrecht et al.
SCIENCE (2016)
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby et al.
NATURE COMMUNICATIONS (2016)
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
M. Cartellieri et al.
BLOOD CANCER JOURNAL (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Vita Golubovskaya et al.
CANCERS (2016)
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL
Shannon L. Maude et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
Wen-ying Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Xiaoou Zhou et al.
BLOOD (2015)
Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
Rachel C. Lynn et al.
BLOOD (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules
Min Soo Kim et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity
De-Gang Song et al.
ONCOTARGET (2015)
Improving the safety of cell therapy with the TK-suicide gene
Raffaella Greco et al.
FRONTIERS IN PHARMACOLOGY (2015)
In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer
Beatrice Clemenceau et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Joanne A. Hammill et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill et al.
IMMUNOLOGICAL REVIEWS (2015)
T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression
Stephen P. Santoro et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Ko Kudo et al.
CANCER RESEARCH (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
Katarzyna Urbanska et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy
Fumihiro Ochi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
Tessa Gargett et al.
FRONTIERS IN PHARMACOLOGY (2014)
Blinatumomab, a bi-specific anti-CD19/CD3 BiTE (R) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications
Lindsey M. Hoffman et al.
FRONTIERS IN ONCOLOGY (2014)
Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice
Dhanalakshmi Chinnasamy et al.
CANCER RESEARCH (2013)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
De-Gang Song et al.
BLOOD (2012)
A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor
Katarzyna Urbanska et al.
CANCER RESEARCH (2012)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells
Virna Marin et al.
HUMAN GENE THERAPY METHODS (2012)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer
Connie P. M. Duong et al.
IMMUNOTHERAPY (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
Carol M. Lee et al.
BMC CANCER (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Affinity and Avidity in Antibody-Based Tumor Targeting
Stephen I. Rudnick et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor
Scott Wilkie et al.
JOURNAL OF IMMUNOLOGY (2008)
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation
Fabio Ciceri et al.
BLOOD (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes
Beatrice Clemenceau et al.
BLOOD (2006)
Adoptive immunotherapy for cancer: building on success
L Gattinoni et al.
NATURE REVIEWS IMMUNOLOGY (2006)
The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
RD Guest et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
PF Robbins et al.
JOURNAL OF IMMUNOLOGY (2004)
分享论文
